These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39386588)

  • 1. Potent and Selective SETDB1 Covalent Negative Allosteric Modulator Reduces Methyltransferase Activity in Cells.
    Uguen M; Shell DJ; Silva M; Deng Y; Li F; Szewczyk MM; Yang K; Zhao Y; Stashko MA; Norris-Drouin JL; Waybright JM; Beldar S; Rectenwald JM; Mordant AL; Webb TS; Herring LE; Arrowsmith CH; Ackloo S; Gygi SP; McGinty RK; Barsyte-Lovejoy D; Liu P; Halabelian L; James LI; Pearce KH; Frye SV
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3K14ac is linked to methylation of H3K9 by the triple Tudor domain of SETDB1.
    Jurkowska RZ; Qin S; Kungulovski G; Tempel W; Liu Y; Bashtrykov P; Stiefelmaier J; Jurkowski TP; Kudithipudi S; Weirich S; Tamas R; Wu H; Dombrovski L; Loppnau P; Reinhardt R; Min J; Jeltsch A
    Nat Commun; 2017 Dec; 8(1):2057. PubMed ID: 29234025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETDB1 Triple Tudor Domain Ligand, (
    Uguen M; Deng Y; Li F; Shell DJ; Norris-Drouin JL; Stashko MA; Ackloo S; Arrowsmith CH; James LI; Liu P; Pearce KH; Frye SV
    ACS Chem Biol; 2023 Aug; 18(8):1846-1853. PubMed ID: 37556795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETDB1 Triple Tudor Domain Ligand, (
    Uguen M; Deng Y; Li F; Shell DJ; Norris-Drouin JL; Stashko MA; Ackloo S; Arrowsmith CH; James LI; Liu P; Pearce KH; Frye SV
    bioRxiv; 2023 May; ():. PubMed ID: 37214894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain.
    Guo Y; Mao X; Xiong L; Xia A; You J; Lin G; Wu C; Huang L; Wang Y; Yang S
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8760-8765. PubMed ID: 33511756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.
    Park I; Hwang YJ; Kim T; Viswanath ANI; Londhe AM; Jung SY; Sim KM; Min SJ; Lee JE; Seong J; Kim YK; No KT; Ryu H; Pae AN
    J Comput Aided Mol Des; 2017 Oct; 31(10):877-889. PubMed ID: 28879500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of the first fragment hits for SETDB1 Tudor domain.
    Mader P; Mendoza-Sanchez R; Iqbal A; Dong A; Dobrovetsky E; Corless VB; Liew SK; Houliston SR; De Freitas RF; Smil D; Sena CCD; Kennedy S; Diaz DB; Wu H; Dombrovski L; Allali-Hassani A; Min J; Schapira M; Vedadi M; Brown PJ; Santhakumar V; Yudin AK; Arrowsmith CH
    Bioorg Med Chem; 2019 Sep; 27(17):3866-3878. PubMed ID: 31327677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer.
    Prashanth S; Radha Maniswami R; Rajajeyabalachandran G; Jegatheesan SK
    Drug Discov Today; 2024 May; 29(5):103982. PubMed ID: 38614159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SETDB1 in cancer: overexpression and its therapeutic implications.
    Lazaro-Camp VJ; Salari K; Meng X; Yang S
    Am J Cancer Res; 2021; 11(5):1803-1827. PubMed ID: 34094655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response.
    Zhao Z; Feng L; Peng X; Ma T; Tong R; Zhong L
    Front Pharmacol; 2022; 13():1073713. PubMed ID: 36582533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functions of SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) in biological process and disease.
    Luo H; Wu X; Zhu XH; Yi X; Du D; Jiang DS
    Epigenetics Chromatin; 2023 Dec; 16(1):47. PubMed ID: 38057834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
    Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
    Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
    Markouli M; Strepkos D; Piperi C
    Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of the ubiquitination-triggered active form of SETDB1 in Escherichia coli for biochemical and structural analyses.
    Funyu T; Kanemaru Y; Onoda H; Arita K
    J Biochem; 2021 Dec; 170(5):655-662. PubMed ID: 34324684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.
    Luo F; Zhang M; Sun B; Xu C; Yang Y; Zhang Y; Li S; Chen G; Chen C; Li Y; Feng H
    Mol Cancer; 2024 Mar; 23(1):60. PubMed ID: 38520019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The H3K9 Methylation Writer SETDB1 and its Reader MPP8 Cooperate to Silence Satellite DNA Repeats in Mouse Embryonic Stem Cells.
    Cruz-Tapias P; Robin P; Pontis J; Maestro LD; Ait-Si-Ali S
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31557926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
    Strepkos D; Markouli M; Klonou A; Papavassiliou AG; Piperi C
    Cancer Res; 2021 Feb; 81(3):525-534. PubMed ID: 33115801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research.
    Ma T; Xu F; Hou Y; Shu Y; Zhao Z; Zhang Y; Bai L; Feng L; Zhong L
    Bioorg Chem; 2024 Apr; 145():107219. PubMed ID: 38377821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial‑mesenchymal transition and PI3K/AKT pathway activation.
    Qian X; Yang Y; Deng Y; Liu Y; Zhou Y; Han F; Xu Y; Yuan H
    Exp Ther Med; 2023 Jun; 25(6):274. PubMed ID: 37206551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.